Why carry out this study?

- Patients with diabetes and declining kidney function present many therapeutic challenges, including the management of comorbidities such as hypertension, hyperlipidemias, cardiovascular disease, anemia, and abnormal bone and mineral metabolism.
- The aim of this review was to provide an overview of relevant product labels, guidelines, and publications related to the appropriate use of antihyperglycemic medications in patients with varying degrees of chronic kidney disease (CKD).

What was learned from the study?

- There are discrepancies between label information and guideline recommendations for use of some medications in patients with diabetes and CKD.
- There is generally a lack both of pharmacokinetic/pharmacodynamic data and clinical studies in patients with advanced CKD, particularly for older medications.
- It will remain a challenge in the near future for clinicians to determine the optimal glycemic targets and medication choices for patients with more advanced CKD, to maximize patient safety and health outcomes.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Eli Lilly and Company. Editorial assistance in the preparation of this manuscript was provided by Caroline Spencer and Duncan Marriott (Rx Communications, Mold, UK) funded by Eli Lilly and Company. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).